Search clinical trials for: Buprenorphine, Tipranavir and ritonavir

Total 1370 results

Yale University
Boehringer Ingelheim

Completed

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir (BUTI)

HIV Infections

United States
Boehringer Ingelheim

Completed

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

HIV Infections
Boehringer Ingelheim

Terminated

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

HIV Infections
Boehringer Ingelheim

Completed

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

HIV Infections

United States, Argentina, Brazil, France, Germany, Italy, Spain
Boehringer Ingelheim

Completed

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

HIV Infections

Germany
Boehringer Ingelheim

Completed

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

HIV Infections

Germany, Italy, Spain
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours

HIV Infections

Spain
Boehringer Ingelheim

Terminated

Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

HIV Infections
Boehringer Ingelheim

Completed

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

HIV Infections

Argentina, Austria, Belgium, Brazil, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Hepatic Insufficiency
Boehringer Ingelheim

Completed

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

HIV Infections

Netherlands, Germany, Canada, United States, France, United Kingdom, Switzerland, Denmark, Australia, Greece, Portugal, Belgium, Italy
Boehringer Ingelheim

Completed

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

HIV Infections

France
Boehringer Ingelheim

Completed

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

HIV Infections
Boehringer Ingelheim

Completed

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

HIV Infections

Romania
Boehringer Ingelheim

Terminated

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

Healthy
Johns Hopkins University
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

HIV Infections

United States
Boehringer Ingelheim

Completed

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

HIV Infections
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

HIV Infections

Spain
Boehringer Ingelheim

Completed

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

HIV Infections

United States, Australia, Canada, Puerto Rico
Boehringer Ingelheim

Completed

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Healthy
Boehringer Ingelheim

Completed

Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

Healthy
Montefiore Medical Center

Recruiting

Low-dose Buprenorphine Initiation for Opioid Use Disorder

Opioid Use Disorder

United States
Boehringer Ingelheim

Completed

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

HIV Infections

United States, Puerto Rico
Boehringer Ingelheim

Completed

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

HIV Infections

Germany
Boehringer Ingelheim

Approved for marketing

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

HIV Infections

United States
Boehringer Ingelheim

Terminated

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

HIV Infections

United States, Argentina, Brazil, Canada, Germany, Italy, Spain
Boehringer Ingelheim

Terminated

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

HIV Infections

United States, Bahamas, Belgium, Canada, France, Germany, Greece, Italy, Portugal, Puerto Rico, Spain, Thailand
Steve N. Caritis, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

Pregnancy | Opiate Addiction

United States
Yale University
Abbott

Completed

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

HIV Infections

United States
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Healthy
Indivior Inc.

Completed

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder | Opioid-related Disorders

United States
Indivior Inc.

Completed

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") (RIME)

Opioid Dependency

France
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Suspended

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Opioid-use Disorder

United States
Boehringer Ingelheim

Approved for marketing

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

HIV Infections

Belgium, Brazil, Canada, Denmark, El Salvador, Greece, Italy, Portugal, Spain
Boehringer Ingelheim

Completed

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

HIV Infections

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Study

Opioid-use Disorder

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine for Prisoners

Heroin Addiction

United States
Indivior Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder

United States
Boehringer Ingelheim

Completed

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

Healthy
Psychiatric University Hospital, Zurich

Unknown

Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches

Heroin Addiction

Switzerland
CBT4CBT, LLC

Completed

CBT4CBT for Office Based Buprenorphine

Opioid-use Disorder

United States
Duke University
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075 (Pharm-OUD-Care)

Opioid Use Disorder

United States
Orexo AB
Worldwide Clinical Trials

Completed

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

Opioid-Related Disorders | Opiate Dependence

United States
Boehringer Ingelheim

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

United States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
Johns Hopkins University

Completed

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

Sickle Cell Disease

United States

3

Subscribe